BR9713237A - Comprimido de liberação controlada de cloridrato de alfuzosina - Google Patents

Comprimido de liberação controlada de cloridrato de alfuzosina

Info

Publication number
BR9713237A
BR9713237A BR9713237-3A BR9713237A BR9713237A BR 9713237 A BR9713237 A BR 9713237A BR 9713237 A BR9713237 A BR 9713237A BR 9713237 A BR9713237 A BR 9713237A
Authority
BR
Brazil
Prior art keywords
layer
alfuzosin hydrochloride
hydrophilic polymers
release
swell
Prior art date
Application number
BR9713237-3A
Other languages
English (en)
Other versions
BR9713237B1 (pt
Inventor
Lauretta Maggi
Ubaldo Conte
Pascal Grenier
Guy Vergnault
Alain Dufour
Francois Xavier Jarreau
Clemence Rauch-Desanti
Original Assignee
Synthelabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9713237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Synthelabo, Jagotec Ag filed Critical Synthelabo
Publication of BR9713237A publication Critical patent/BR9713237A/pt
Publication of BR9713237B1 publication Critical patent/BR9713237B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<"COMPRIMIDO DE LIBERAçãO CONTROLADA DE CLORIDRATO DE ALFUZOSINA".>Comprimido farmacêutico destinado à via oral para a liberação controlada de cloridrato de alfuzosina ao nível dos segmentos proximais do trato gastrintestinal, caracterizado pelo fato de ser constituído por: a) uma primeira camada (1) com a propriedade de inchar acentuada e rapidamente em contato com líquidos biológicos aquosos, a dita camada sendo produzida pela compressão de uma mistura ou de um granulado compreendendo polímeros hidrofílicos que constituem de 5,0 a 90%, de preferência de 10 a 85% do peso da camada, b) uma segunda camada (2) adjacente ou superposta à primeira camada, em que o cloridrato de alfuzosina é veiculado, essa camada sendo formulada com polímeros hidrofílicos e com outras substâncias auxiliares para conferir à preparação propriedades de compressibilidade convenientes e par permitir a liberação do cloridrato de alfuzosina em um intervalo de tempo predeterminado, c) e eventualmente uma terceira camada (3), obtida por compressão e aplicada sobre a camada (2), genericamente constituída particularmente por polímeros hidrofílicos que formem um gel e/ou inchem, depois possam eventualmente se erodir, e com a função de barreira moduladora da liberação do cloridrato de alfuzosina da camada (2), a camada (3) sendo inicialmente muito pouco permeável à passagem da substância ativa. Composição farmacêutica.
BRPI9713237-3A 1996-08-29 1997-08-22 comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo. BR9713237B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (2)

Publication Number Publication Date
BR9713237A true BR9713237A (pt) 2000-04-04
BR9713237B1 BR9713237B1 (pt) 2009-01-13

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713237-3A BR9713237B1 (pt) 1996-08-29 1997-08-22 comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.

Country Status (36)

Country Link
US (1) US6149940A (pt)
EP (1) EP0938318B1 (pt)
JP (1) JP3797388B2 (pt)
KR (1) KR100364328B1 (pt)
CN (2) CN1155382C (pt)
AP (1) AP1107A (pt)
AR (1) AR009312A1 (pt)
AT (1) ATE200864T1 (pt)
AU (1) AU724490B2 (pt)
BG (1) BG63768B1 (pt)
BR (1) BR9713237B1 (pt)
CA (1) CA2264250C (pt)
CO (1) CO4920217A1 (pt)
CY (1) CY2284B1 (pt)
CZ (1) CZ295066B6 (pt)
DE (1) DE69704712T2 (pt)
DK (1) DK0938318T3 (pt)
EE (1) EE03855B1 (pt)
ES (1) ES2159400T3 (pt)
GR (1) GR3036291T3 (pt)
HU (1) HU228007B1 (pt)
IL (1) IL128146A (pt)
IS (1) IS2091B (pt)
MX (1) MXPA99001958A (pt)
NO (1) NO326206B1 (pt)
NZ (1) NZ334018A (pt)
OA (1) OA10983A (pt)
PL (1) PL191546B1 (pt)
PT (1) PT938318E (pt)
RU (1) RU2183459C2 (pt)
SI (1) SI0938318T1 (pt)
SK (1) SK284388B6 (pt)
TR (1) TR199900289T2 (pt)
TW (1) TW522023B (pt)
UA (1) UA69374C2 (pt)
WO (1) WO1998008515A1 (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
EP1556014A1 (en) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Sustained release compositions containing alfuzosin
KR20070043806A (ko) * 2004-07-29 2007-04-25 사노피-아벤티스 ｐＨ에 매우 의존적인 용해도를 가지는 활성 성분의 제어방출을 위한 약제학적 다층 정제
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
EP2671507A3 (en) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
JP5296531B2 (ja) 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US8206742B2 (en) 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
EP2013829A4 (en) 2006-05-02 2010-07-07 Proteus Biomedical Inc PERSONALIZED THERAPEUTIC REGIMES FOR A PATIENT
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
WO2008052136A2 (en) 2006-10-25 2008-05-02 Proteus Biomedical, Inc. Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc PERSONAL HEALTH SIGNAL RECEIVERS WITH ACTIVE SIGNAL PROCESSING
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
EP3785599B1 (en) 2007-02-01 2022-08-03 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker systems
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
EP2124725A1 (en) 2007-03-09 2009-12-02 Proteus Biomedical, Inc. In-body device having a multi-directional transmitter
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
ES2928197T3 (es) 2007-09-25 2022-11-16 Otsuka Pharma Co Ltd Dispositivo intracorpóreo con amplificación de señal de dipolo virtual
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK3235491T3 (da) 2008-03-05 2021-02-08 Otsuka Pharma Co Ltd Spiselige hændelsesmarkeringsenheder og systemer med multimodus-kommunikation
BRPI0913398A2 (pt) * 2008-06-04 2015-11-24 Procter & Gamble composição e métodos de adesivo para dentaduras
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
CN104382598A (zh) 2008-08-13 2015-03-04 普罗透斯数字保健公司 一种产生识别器的方法
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
CA2750148C (en) 2009-01-06 2017-02-07 Proteus Biomedical, Inc. Pharmaceutical dosages delivery system
AU2010203625A1 (en) 2009-01-06 2011-07-21 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
BR122013009559A2 (pt) 2009-04-28 2019-08-06 Proteus Digital Health, Inc. Marcadores de evento de ingerível altamente confiável e métodos para usar os mesmos
EP2432458A4 (en) 2009-05-12 2014-02-12 Proteus Digital Health Inc ACCEPTABLE EVENT MARKER WITH SUGAR COMPONENT
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
AU2011224486B2 (en) 2010-03-10 2014-08-14 The Procter & Gamble Company Denture adhesive compositions
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2011127252A2 (en) 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
BR112014001397A2 (pt) 2011-07-21 2017-02-21 Proteus Biomedical Inc dispositivo, sistema e método de comunicação móvel
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
EP2874886B1 (en) 2012-07-23 2023-12-20 Otsuka Pharmaceutical Co., Ltd. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
JP2016508529A (ja) * 2013-01-29 2016-03-22 プロテウス デジタル ヘルス， インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
JP6511439B2 (ja) 2013-06-04 2019-05-15 プロテウス デジタル ヘルス， インコーポレイテッド データ収集および転帰の査定のためのシステム、装置、および方法
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
SG10202101937PA (en) 2016-07-22 2021-03-30 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
WO2018081337A1 (en) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Methods for manufacturing capsules with ingestible event markers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
ATE200864T1 (de) 2001-05-15
AP1107A (en) 2002-09-20
IS4964A (is) 1999-01-29
US6149940A (en) 2000-11-21
DK0938318T3 (da) 2001-08-20
KR100364328B1 (ko) 2002-12-26
UA69374C2 (uk) 2004-09-15
CN1543954A (zh) 2004-11-10
CY2284B1 (en) 2003-07-04
EE03855B1 (et) 2002-10-15
PL191546B1 (pl) 2006-06-30
IL128146A0 (en) 1999-11-30
JP2000514462A (ja) 2000-10-31
WO1998008515A1 (fr) 1998-03-05
CZ295066B6 (cs) 2005-05-18
ES2159400T3 (es) 2001-10-01
TR199900289T2 (xx) 2000-12-21
NZ334018A (en) 1999-06-29
PL331862A1 (en) 1999-08-16
IS2091B (is) 2006-03-15
IL128146A (en) 2001-01-11
CN100335057C (zh) 2007-09-05
GR3036291T3 (en) 2001-10-31
NO990944D0 (no) 1999-02-26
BG103138A (en) 1999-09-30
OA10983A (fr) 2003-03-04
NO990944L (no) 1999-04-27
NO326206B1 (no) 2008-10-20
CA2264250A1 (en) 1998-03-05
HUP9903428A3 (en) 2000-04-28
MXPA99001958A (es) 2005-09-08
AU724490B2 (en) 2000-09-21
CO4920217A1 (es) 2000-05-29
EP0938318A1 (fr) 1999-09-01
TW522023B (en) 2003-03-01
PT938318E (pt) 2001-10-30
DE69704712T2 (de) 2001-11-29
JP3797388B2 (ja) 2006-07-19
SK27099A3 (en) 1999-12-10
RU2183459C2 (ru) 2002-06-20
HUP9903428A2 (hu) 2000-02-28
CA2264250C (en) 2005-07-05
SI0938318T1 (en) 2001-12-31
HU228007B1 (en) 2012-08-28
AR009312A1 (es) 2000-04-12
HK1020875A1 (en) 2000-05-26
EP0938318B1 (fr) 2001-05-02
KR20000035929A (ko) 2000-06-26
CZ65599A3 (cs) 1999-06-16
AU4020197A (en) 1998-03-19
EE9900090A (et) 1999-10-15
BR9713237B1 (pt) 2009-01-13
SK284388B6 (sk) 2005-02-04
AP9901470A0 (en) 1999-03-31
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
BG63768B1 (bg) 2002-12-29
CN1228700A (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
BR9713237A (pt) Comprimido de liberação controlada de cloridrato de alfuzosina
Kamada et al. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice
Guggi et al. Systemic peptide delivery via the stomach: in vivo evaluation of an oral dosage form for salmon calcitonin
BRPI0110038C1 (pt) comprimido de liberação controlada de multicamada contendo ropinirol, e, uso de ropinirol
KR890004684A (ko) 신속 방출제 전달계와 완속 방출제 전달계로 된 제형(劑刑)
Scarpignato Piroxicam-β-cyclodextrin: a GI safer piroxicam
ATE415941T1 (de) Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR0211546A (pt) Composição farmacêutica e/ou de diagnóstico e uso de microrganismo ou célula
CY1107512T1 (el) Νεες υποκατεστημενες με βενζιμιδαζολιο μορφες δοσολογιας και μεθοδος για τη χρηση τους
EA200702187A1 (ru) Композиция таблетки прамипексола с замедленным высвобождением
BR9811793A (pt) MacrÈmeros biodegradáveis para a liberação controlada de substâncias biologicamente ativas.
ATE300286T1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
DE60133319D1 (de) Mehrfach beschichete pharmazeutische dosierungsform
ES2086029T3 (es) Composiciones farmaceuticas solidas para la administracion oral con permanencia gastrica prolongada.
US20070219286A1 (en) Adhesive For Dermal Patch And Production Process Thereof
ES2162874T3 (es) Composicion farmaceutica para hacer llegar medicamentos hasta el colon.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
Furtado et al. Development and characterization of orodispersible tablets of famotidine containing a subliming agent
Chen et al. Biodegradable polymer–mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model
BR0012400A (pt) Composição de liberação continuada, método para produzir composição de liberação continuada, medicamento, e, agente profilático ou terapeutico
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
AR002049A1 (es) Una composicion farmaceutica para la administracion oral de agentes activos que tienen baja solubilidad en agua y el procedimiento para prepararla
CN119233828A (zh) 纳米胶囊化药物组合物及其用途

Legal Events

Date Code Title Description
PC Transfer

Free format text: JAGOTEC AG (CH), SANOFI-SYNTHELABO (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 9/22, A61K 31/517, A61P 13/08

Ipc: A61K 9/22, A61K 31/517, A61P 13/08

B25D Requested change of name of applicant approved

Owner name: JAGOTEC AG (CH) , SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 10.03.2019